Savi Quetiapine 25 medicine for schizophrenia (3 blisters x 10 tablets)

Dosage form Box of 3 blisters x 10 tablets
Specifications Quetiapina

Ingredient

Composition informationContent
Quetiapina25mg

Uses

Indications

Quetiapine 25 drugs are indicated in the following cases:

schizophrenia treatment.

Treatment of bipolar disorder includes:

Treatment of average to severe revolutionary attacks related to bipolar disorders.

Treatment of depression related to bipolar disorder.

Room recurrence of a rise or depression in bipolar disorder patients with Quetiapin treatment.

Pharmacokological

Quetiapin is active through tests on anti -psychotic effects, such as Conditailed Avoidance.

Quetiapin also reverses the impact of homogeneous substances with dopamine, evaluated by behavior or physiological and increases the concentration of dopamine metabolites, the nerve chemical index of Dopamine receptor inhibitors D2.

In preclinical trials forecasting the possibility of foreign symptoms (EPS: Extrapyramidal Symptoms), Quetiapin is not like typical anti -psychotic drugs and has no typical characteristics.

Quetiapin does not cause hypersensitivity to Dopamine D2 receptor when used for long term. Quetiapin only causes weak impact (catalepsy) in the doses of Dopamine D2 receptors. Quetiapin proves the selection on the edge of the brain through the reducing inhibition effect of dopamine neurons in the middle edge of the brain but does not impact on nigrostriatal neurons after long -term use. Immediately after taking the drug and in the long run, Quetiapin can cause very small muscle disorders on Cebus monkeys sensitive to Haloperidol or not.

Mechanism of action

Quetiapin is an aligned anti -psychotic drug. Quetiapin and metabolites are active in human plasma, Norquetiapin has the effects on many types of neurotransmitter receptors. Quetiapin and Norquetiapin are affinity for serotonin receptors (5ht2 in the brain and with Dopamine D1 and D2 receptors. The selective is with Serotonin receptor (5HT2) in the brain higher with Dopamine D2 receptor is believed to contribute to clinical anti -psychotic properties and have little risk of side effects on the pagoda of Quetiapin tower.

In addition, Norquetiapin has high affinity with norepinephrin transportation. Quetiapin and Norquetiapin also have high affinity with histaminergic receptors and adrenergic alpha1, with lower affinity with adrenergic alpha2 receptors, and Serotonin 5HT1A. Quetiapin has negligible affinity for the Cholinergic Muscarinic or Benzodiazepin receptors.

pharmacokinetics

Adults

The activity of Quetiapin Fumarat is mainly due to the original compound. Quetiapine multi -dose pharmacokinetics are linearly in the clinical dose of proposed, and accumulating Quetiapin is predicted when used many times. Quetiapin elimination is mainly through the liver metabolism with the last half of the last half of the proposed clinical dose. The concentration in a stable state is expected to be achieved within 2 days of medication. Quetiapin does not interfere with the metabolism of the drug metabolized by the cytochrom P450 enzyme.

Children and teenagers

Dynamic data in 9 children from 10 - 12 years old and 12 teenagers have stable treatment with 400mg of quetiapin twice daily. In a stable state, Quetiapin plasma concentration in children and teenagers (10-17 years old) is similar in adults, although CMAX in children is higher than adults. AUC (Area Under the Curve) and CMAX of metabolites are about 62% higher than 62% and 49% in children, 28% and 14% respectively in adolescents (13 - 17 years old) compared to adults.

absorption

Quetiapin Fumarat is quickly absorbed after drinking, reaching a plasma peak concentration after 1.5 hours. The bioavailability of Quetiapin is slightly affected when taken with food, whereby the value of CMAX and AUC increases 25% and 15%, respectively.

Distribution

Quetiapin is widely distributed throughout the body with a distribution volume of 10 ± 4 liters/kg. 83% of drugs are associated with plasma proteins at the concentration of treatment. In vitro test shows that Quetiapin does not affect the links of Warfarin or Diazepam with human serum albumin. In contrast, Warfarin or Diazepam also does not change the links of Quetiapin.

Metabolism and elimination

After taking the only dose with 14C-Quetiapin radioactive, less than 1% of the dose is eliminated in the form of constant, showing that Quetiapin is very strongly metabolized. About 73% and 20% of the dose is recovered in urine and feces, respectively.

quetiapin is metabolized in the liver. The main metabolic paths are sulfoxid chemicals with sulfoxid metabolites and oxidation of parent acid metabolites, both of these metabolites are not active.

In In vitro studies using Human Liver Microsom shows that CYP3A4 has been involved mainly in the metabolism of quetiapin through cytochrom P450 intermediaries and Norquetiapin metabolites have the main activity formed and eliminated via CYP3A4.

Before taking Savi Quetiapine 25 medicine for schizophrenia (3 blisters x 10 tablets)

How to use

oral drugs. Drink during or outside meals.

Dosage

The dosage of drug used is calculated according to quetiapin.

Every 28.79mg of quetiapin fumarat is equivalent to 25mg quetiapin.

Adults

schizophrenia

quetiapin should drink 2 times/day. The total daily dose in the first 4 days of treatment is 50mg (daily 1), 100mg (daily 2), 200mg (dated 3), 300mg (day 4). From the 4th day onwards, the dose should be mainly to be effective, usually from 300 - 450mg/day. Depending on the clinical response and tolerance of each patient, the dose can be adjusted in the range of 150 - 750 mg/day.

Treatment of average to severe revolutionary attacks related to bipolar disorders

quetiapin should drink 2 times/day. The total daily dose in the first 4 days of treatment is 50mg (daily 1), 100mg (daily 2), 200mg (dated 3), 300mg (day 4). Increase the dose, reaching 800mg/day on the 6th day, should not increase more than 200mg/day. Depending on the clinical response and tolerance of each patient, the dose can be adjusted in the range of 200 - 800mg/day. Effective doses are usually about 400 - 800mg/day.

Treatment of depression related to bipolar disorder

quetiapin should drink 1 time/day before going to bed. The total daily dose in the first 4 days of treatment is 50mg (daily 1), 100mg (daily 2), 200mg (dated 3), 300mg (day 4). The daily dose is promoted as 300mg. The larger dose should be started by experienced doctors in the treatment of bipolar disorders. In each case, clinical trials show that the dose can be reduced to 200mg.

Room recurrence of emotional or depression in patients with bipolar disorder

In order to prevent relapse of emotional, depression or mixture in bipolar disorders, the patient has responded to treatment with Quetiapin in the treatment of acute bipolar disorders, so they continue to treat with the same dose. The dose may be adjusted depending on the clinical response and tolerance of each disease, in the range of 300 - 800mg/day, 2 times/day. The most effective dose is used for maintenance treatment.

Elderly

Like other anti -psychotic drugs, should be cautious when using Quetiapin in the elderly, especially in the starting stage of using the drug. The frequency of adjusting the dose may need to be reduced and the daily dose is lower than young people, depending on the clinical response and tolerance of each patient. The clearance of Quetiapin in the elderly decreased by 30-50% compared to young people.

The effectiveness and safety of Quetiapin has not been evaluated in depression patients related to bipolar disorder over 65 years old.

children and adolescents

Quetiapin is not recommended for children and teenagers under 18 years old.

kidney failure

No dose adjustment in kidney failure.

liver failure

quetiapin metabolizes in the liver. Therefore, the kidneys need to be used while using quetiapin in patients with hepatic failure, especially in the early stages of treatment. Patients with liver failure should start treatment at a dose of 25mg/day. The daily dose should be increased daily about 25 - 50mg/day until it is effective, depending on the clinical response and tolerance of each patient.

Note: The above dose is for reference only. Specific dosage depends on the condition and level of progression of the disease. For a suitable dose, you need to consult a doctor or medical specialist.

What to do when overdose?

Symptoms

In general, signs and symptoms are due to an increase in pharmacological impact of the drug, such as vaginal and sedative, tachycardia, hypotension and acetylcholine resistance.

Overdose can lead to extension of QT, convulsions, epilepsy, pattern, respiratory failure, urinary retention, confusion, delusion or excitement, coma and death. Patients with previous severe cardiovascular disease may increase the risk of overdose.

Handling

There is no specific detoxification for Quetiapin. In case of severe poisoning, it is necessary to consider the ability of many drugs, taking special care measures, including establishment and maintenance of airway, ensuring ventilation and adequate oxygen supply, monitoring and cardiovascular support.

Based on the published document, patients with paranoid symptoms, agitation and acetylcholine resistance syndrome are clearly treated with physostigmin, 1 - 2 mg (continuous electrocardiogram tracking). This is not a standard treatment recommendation because of the potential negative effects of Physostigmin on the heart. Physostigmin can be used if there is no problem with electrocardiography (ECG: ElectrocardRam). Do not use physostigmin in case of arrhythmia (any level) or qRS widening.

Research on reducing quetiapin absorption in the overdose has not been conducted. In case of severe poisoning, the stomach may be done within an hour after overdose. Activated carbon can be used to reduce the absorption of Quetiapin.

In case of quetiapine overdose, hypotension should be treated with appropriate measures such as intravenous fluid or sympathetic drugs. Epilephrin and dopamine should be avoided because beta stimulation can lower blood pressure. Need to continue monitoring and monitoring patients closely until complete recovery.

What to do when you forget a dose? However, if close to the next dose, skip the forgotten dose and take the next dose at the time as planned. Note that it should not be used double the prescribed dose.

Side Effects

When using Quetiapine 25, you may experience unwanted effects (ADR).

Sleep, dizziness, dry mouth, mild weakness, constipation, tachycardia, standing blood pressure and indigestion.

Fainting, malignant syndrome caused by sedation, leukopenia, neutropenia and peripheral edema may occur.

Very common, ADR ≥ 1/10

Nervous dysfunction: dizziness, dizziness (1.5), drowsiness (2).

Common, ADR> 1/100

Nervous dysfunction: fainting (1.5).

Respiratory, chest and medical dysfunction: rhinitis.

Hematoma and lymphatic dysfunction: leukopenia.

heart dysfunction: tachycardia (1.5).

Vascular dysfunction: Hypotension (1.5).

Disorders of the digestive system: dry mouth, constipation, indigestion.

Side effects on the spot and whole body: mild weakness, peripheral edema.

Subclinical: Weight gain (3), Serum transaminase (Alt: Alanine Aminotransferase, AST: Aspartate Aminotransferase) (4).

Neutral leukopenia (7).

Blood sugar increases to pathological level (8).

Uncommon, 1/1000

Disorders of hyperemia and lymphatic system: hyperlypes.

immune system dysfunction: hypersensitivity.

Subclinical: Gamma-AG increased (4), increased serum triglycerides at any time, increased total cholesterol (mainly LDL-C).

Nervous system dysfunction: convulsions (1), Run Syndrome.

Rare, ADR

Side effects on the spot and whole body: Malignant syndrome due to sedative (1).

Genital dysfunction: erectile dysfunction.

Very rare, ADR

immune system disorders: Anaphylactic reaction (6).

Note:

(1) See the "Warning and Caution when used".

(2) Sleep may occur, usually in the first 2 weeks and disappear when continuing treatment with Quetiapin.

(3) mainly occurs during the weeks to start treatment with the drug.

(4) Askoned symptoms of serum transaminase (ALT, AST) or gamma-AG increased in some patients using Quetiapin. These increase often recover when continuing treatment with quetiapine.

(5) As well as alpha1-adrenergic inhibitors, quetiapin can cause vertical hypotension, accompanied by dizziness, tachycardia and fainting in some patients, especially in the first stage of dose adjustment.

(6) Anaphylactic reaction was put into reports after the drug was brought to the market.

(7) In all clinical trials that are controlled with a placebo on patients with leukemia when starting with testing ≥ 1.5 x 109/l, the frequency occurs at least once a neutral leukemia test

On clinical trials before adjusting the research outline to stop the drug for patients with neutropen leukemia 1.5 x 109/l, the frequency occurs at least once a neutral leukocyte test

(8) Blood glucose at ≥ 126mg/dl or blood glucose at any time ≥ 200mg/dl occurs at least in one test.

Instructions on how to handle ADR

If serious ADR occurs, stop taking medication and apply appropriate treatments.

Warnings

Before using the drug you need to read the instructions carefully and refer to the information below.

Contraindicated

Quetiapine 25 contraindicated drug in the following cases:

  • Hypersensitivity to Quetiapin or any ingredients of the drug.
  • Collaborate with cytochrom P450 3A4 inhibitors such as HIV -resistant Protease, anti -Azole, erythromycin, Clarithromycin and Nefazodon.

    • Precautions when using

    The conditions need to be cautious when taking the drug.

    Children

    Quetiapin is not recommended for children and teenagers under 18 years of age due to lack of data of drugs in this age group. Clinical trials show that some side effects have a higher frequency of children and adolescents in adults (increasing appetite, high serum prolactin, vomiting, rhinitis, fainting) or may have different effects in children and young people (symptoms of foreign tower, stimulated) and hypertension. The effects on the thyroid function also observed.

    Moreover, the safety in long -term treatment with quetiapin has not been studied for more than 26 weeks.

    In clinical trials in children and teenagers treat schizophrenia, bipolar and bipolar depression, the research results show that the symptoms of extravagance are increased in the group of patients treated with quetiapine compared to the placebo group.

    suicide/intend to commit suicide

    Depression is associated with an increase in the risk of suicide, self -destruction and suicide (suicidal events). This risk lasts until the disease is significantly reduced. Because the improvement of the disease may not appear in the first few weeks of treatment or longer, the patient should be closely monitored until the disease is significantly improved. Clinical experience shows that the risk of suicide may increase in the early stages of the recovery process.

    In addition, the doctor should consider the potential risk of suicide when stopping sudden treatment with Quetiapin.

    Patients with a history of suicide, or suicide thought before treatment may be at risk of suicide and highly suicidal thoughts and need to be closely monitored during treatment. Clinical research with placebo -controlled control of antidepressants in adult patients with mental disorders shows that in the treatment group with antidepressants, there is an increase in the risk of suicide in patients under 25 years older than the group using Placebo.

    Monitoring patients, especially those at high risk of suicide, should be performed along with drug treatment, especially in the early stages of the treatment process and when changing the dose. Patients (and patient care) should be warned of the need to monitor the deterioration, suicide behavior or abnormal changes in thinking and behavior. Find medical advice immediately if these symptoms appear. Clinical studies in depression patients related to bipolar disorders show that the risk of suicide in patients under 25 years of age has been treated with quetiapin increased compared to those who treated with Placebo (equivalent to 3.0% compared to 0%).

    Metabolism

    Clinical studies show that the metabolism changes in the direction of worsening, including changes in weight, blood glucose and lipid. The patient's metabolic parameters should be evaluated at the start of treatment and parameters should be controlled regularly during treatment. These parameters should be monitored as a clinical sign.

    Symptoms of foreign tower

    Clinical clinical studies in adult patients show that Quetiapin is associated with an increase in the incidence of foreign symptoms compared to the placebo group in patients who treat severe depression in bipolar disorders. The use of Quetiapin makes Akathisia's restless restlessness characterized by restlessness, subjective insecurity and must move regularly to sit or stand still. This may occur in the first few weeks of treatment. In patients with this symptom, increased dose can be harmful.

    Late movement disorders

    If the signs and symptoms of late movement disorders appear, the dose reduction or quetiapine stops. Symptoms of late movement disorders may be severe or appear after stopping treatment.

    Sleep and dizziness

    Like sedatives, treatment with quetiapin can cause drowsiness and related symptoms. In clinical trials to treat bipolar depression patients, the onset is usually within the first three days of treatment and the main level from mild to medium. Patients with severe intensity must be re -examined more often, at least 2 weeks from the beginning of drowsiness or until symptoms improve. Patients with severe intensity may have to stop treatment.

    posture hypotension

    quetiapin can cause vertical and dizziness. Hypotension posture usually starts at the starting dose and the dose adjustment stage. This may increase the risk of injury due to an accident (fall), especially in the elderly. Therefore, patients should be cautious until they are familiar with the side effects of the drug.

    Be cautious when using quetiapin in patients with cardiovascular disease, cerebrovascular disease, or other pathological conditions that can cause hypotension. If hypotension occurs, it is advisable to consider reducing the dose or increasing the dose slowly, especially in patients with cardiovascular disease.

    Sleep apnea syndrome

    Sleep apnea syndrome has been reported in patients using Quetiapin. In patients who use simultaneously with antidepressants and people with a history or a risk of sleep apnea, such as overweight/obesity or men, Quetiapin should be used carefully.

    epilepsy

    In control clinical trials, there is no difference in the rate of convulsions in patients treated with quotiapin or placebo. There is no data on convulsions in patients with a history of convulsions. Like other anti -psychotic drugs, it is necessary to be cautious when using Quetiapin to treat patients with convulsions.

    malignant syndrome due to sedative

    Malignant syndrome caused by neuroleptic is related to the treatment of anti -psychotic drugs, including Quetiapin. Clinical manifestations include overcrowding, mental changes, muscle spasms, unstable autonomous nervous systems and increased creatin phosphokinase. In this case, Quetiapin should be discontinued and appropriate treatment.

    Neutral leukemia and grain leukemia

    Heavy neutropenia (

    neutropenia should be considered in infections or fever patients, especially in the absence of clear causes, and must be clinically monitored.

    Patients should be advised to report as soon as the signs/symptoms are related to granulocytes or infections (for example, fever, weakness, indifference, or sore throat) whenever treatment with Quetiapin.

    Acetylcholin resistance effect

    Norquetiapin is a metabolic substance that has the activity of Quetiapin, has a strong average affinity with many types of Muscarinic receptors. This contributes to acetylcholine resistance when quetiapin is used in the recommended dose, when used simultaneously with other drugs that have acetylcholine resistance, and in case of overdose. Use Quetiapin cautiously in patients taking anti -acetylcholine drugs (Muscarinic). Quetiapin should be used carefully in patients with current diagnosis or history of urinary retention, prostate hypertrophy with clinical significance, intestinal obstruction or related diseases, glaucoma or closed angle glaucoma.

    Drug interaction

    Simultaneous use of Quetiapin with strong liver enzyme drugs such as carbamazepine or phenytoin reduces the plasma concentration of quetiapin. This may affect Quetiapin's treatment effect. Patients who are taking liver enzyme drugs, only starting to treat Quetiapin when Quetiapin's treatment benefits are higher than the risk of liver enzyme stopping. The important thing is that any liver enzyme changes should be changed slowly, if necessary, it can be replaced with liver enzyme non -touch drugs (such as sodium valproat).

    weight

    Weight gain has been reported in patients treated with Quetiapin and should be monitored and clinically monitored as instructions for using anti -psychotic drugs.

    Hyperglycemia

    Hyperglycemia or hyperglycemia or acute hyperglycemia sometimes combined with keratical acid infection or coma rarely occurs, including death. In some cases, previous weight gain has been reported, this may be a cause. Clinical monitoring should be monitored according to the instructions for using anti -psychotic drugs. Patients who use any anti -psychotic drugs include Quetiapin, so monitor signs and symptoms of hyperglycemia (such as drinking, urinating, eating a lot and tired), and patients with diabetes or has risk factors for diabetes, so they monitor blood sugar regularly. Should monitor regular weight.

    lipid

    Increase triglycerides, LDL (Low Density Lipoprotein) and total cholesterol, and HDL reduction (High Density Lipoprotein) cholesterol has been observed in clinical trials with quetiapin. Lipid changes should be clinically monitored.

    extends the range of qt

    In clinical studies and use of the statistical process Control (Statistical Process Control) Quetiapin has no side effects that extend the QT range. During the use of the drug, the Quetiapin report extends the QT range at the treatment dose and in case of overdose. Like other anti -psychotic drugs, using caution quetiapin in patients with cardiovascular disease or family history has a QT range. In addition, it is necessary to be cautious when using Quetiapine simultaneously with drugs that extend the QT or sedative, especially in the elderly, patients with congenital QT syndrome, congenital heart failure, heart hypertrophy, hypotension or hypoglycemia.

    Myocarditis and myocarditis

    Myocarditis and myocarditis have been reported. However, the causal relationship with Quetiapin has not been studied. Treatment with Quetiapin should be reviewed in patients suspected of myocardial or myocarditis.

    Stop using drugs

    Symptoms of acute cessation such as insomnia, nausea, headache, diarrhea, vomiting, dizziness and discomfort have been described after stopping the Quetiapin suddenly. Quetiapine should be stopped gradually for at least 1-2 weeks.

    Elderly patients with mental disorders.

    Quetiapin is not indicated to treat intellectual dementia associated with mental disorders. Random fatal control tests in patients with dementia with some typical anti -psychotic drugs show the risk of side effects of brain vascular complications increasing 3 times. The mechanism increases this risk unknown. This increased risk is not excluded in other anti -psychotic drugs or other patients. Should be cautious when using Quetiapin in patients with roly risk factors.

    A study on non -typical anti -psychotic drugs shows that elderly patients who have dementia in mental disorders are at higher risk of death compared to the placebo group. In two 10 -week placebo -control studies with Quetiapin, the same group of patients (n = 710, age: 56 - 99 years old, an average of 83 years old), the mortality rate in patients treated with Quetiapin is 5.5% compared to 3.2% in the placebo group.

    Difficult to swallow

    Difficult to swallow has been reported to Quetiapin. Use cautious quetiapin in patients at risk of inhaling pneumonia.

    Constipation and intestinal obstruction

    Constipation is a risk factor for bowel obstruction. Constipation and intestinal obstruction have been reported to Quetiapin, including death reports in patients at high risk of intestinal obstruction, users simultaneously reducing intestinal peristalsis and/or may not report constipation symptoms. Patients with intestinal obstruction/intestinal obstruction must be closely monitored and special medical care.

    Venous thrombosis

    Cases of venous thrombosis (VTE: Venous Thromboembolism) have been reported to anti -psychotic drugs. Because patients are treated with psychotic drugs, VTE risk factors often appear, all VTE risk factors need to be determined before and during treatment with quetiapine and take preventive measures.

    Pancreatitis

    Pancreatitis is reported in clinical trials and during the use of drugs.

    Abuse and addiction

    Cases of abuse and drug addiction have been reported. Precautions when prescribing Quetiapin for patients with a history of alcoholism or drug addiction.

    Medicine combination

    Data on Quetiapin combination with divalproex or lithium treatment of acute impulsive attacks is limited. However, this combination therapy is effective. The effectiveness of treatment appears at the 3rd week.

    lactose

    Products contain lactose excipients. Patients have rare genetic problems such as galactose intolerance, lactase deficiency or Glucose-Galactose under absorption should not be taken.

    The ability to drive and operate machinery

    Because Quetiapin can cause drowsiness, patients need to be cautious when driving and operating machinery.

    Pregnancy

    In the first three months

    Based on the results of some individual reports and some observation studies, Quetiapin does not increase the risk of fetal defects. However, the data is limited, so it is not possible to make an accurate conclusion. So Quetiapin is only for pregnant women when the treatment benefits are higher than the potential risk.

    The last three months of pregnancy

    Infants are exposed to anti -psychotic drugs (including Quetiapin) in the last three months of pregnancy, there is a risk of extra -life side effects or symptoms of cessation after birth. There has been a report of inciting side effects, increasing muscle tone, reducing muscle tone, tremor, drowsiness, respiratory failure or eating disorders. Therefore, closely monitoring babies.

    Breastfeeding period

    So far, information about quetiapin excretion into human milk is limited. Based on the published information, Quetiapin does not excrete on breast milk at the treatment dose. However, due to lack of information, the decision to stop breastfeeding or stop treatment with Quetiapin depends on the importance of the drug for the mother.

    Drug interaction

    quetiapin mainly acting on the central nervous system, so be careful when coordinating Quetiapin with other medications on other central nervous systems and alcohol.

    Be cautious when using quetiapin for patients being treated with acetylcholin anti -acetylcholin (mucarinic) drugs.

    Quetiapin metabolizes mainly thanks to the cytochrom P450 enzyme (CYP) 3A4, Cytochrom P450 enzyme system. In a study in a healthy volunteer, simultaneously used Quetiapin (dose of 25mg) with ketoconazole, a CYP3A4 inhibitor, increasing 5-8 times the area under the curve of Quetiapin (AUC: Area Under the Curve). On this basis, contraindicated use of Quetiapin with CYP3A4 inhibitors. Grapefruit juice is also not recommended during treatment with Quetiapin.

    In a multi -drug test to evaluate the pharmacokinetics of Quetiapin before and during the treatment process with carbamazepin (a liver enzyme induction), the results showed simultaneous use with carbamazepine significantly increasing the liquid of quetiapin. Increasing clearance reduces Quetiapin exposure (measured by AUC) on average 13% compared to the solitary quetiapin, in some cases of this actor greater. This interaction may reduce the plasma concentration of Quetiapin, which can lead to Quetiapin's therapeutic effect. Simultaneous use of quetiapin with phenytoin (another enzyme induction drug) increases the clearance of quetiapin about 450%. Patients who are taking liver enzyme drugs, only starting to treat Quetiapin when Quetiapin's treatment benefits are higher than the risk of liver enzyme stopping (such as sodium valproat).

    The pharmacokinetics of Quetiapin does not change significantly when combined with imipramine antidepressants (CYP2D6 inhibitors) or fluoxetin (CYP3A4 and CYP2D6 inhibitors).The pharmacokinetics of Quetiapin does not change significantly when combined with Risperidon or Haloperidol psychotic drugs. However, the combination of quetiapin and thioridazin increases the clearance of Quetiapin about 70%. The pharmacokinetics of Quetiapin does not change when combined with cimetidine. lithium pharmacokinetics does not change when combined with quetiapin.

    In a 6 -week random study, Lithi and Quetiapin release the prolonged release of Placebo and Quetiapin release in an adult patient with acute Hung Cam attack, the results showed that the percentage of symptoms of the pagoda, drowsiness and weight gain observed in the Lithi and Quetiapin groups extended higher than Placebo.

    Dynamic pharmacokinetics of sodium valproat and quetiapin clinically unchanged when used in combination. A recovery study in children and teenagers treated with Valproat, Quetiapin or both, research showed a high percentage of neutrophils and neutrophils in the group used to combine compared to the single -treatment group.

    Quetiapin interaction with cardiovascular medications is not used yet.

    Be careful when using Quetiapin simultaneously with drugs that cause insomnia of electrolytes and increase QT.

    Methadone immune test and three -round antidepressants can give false positive results in patients being treated with quetiapin.

    Storage

    In a dry place, avoid light, temperature below 30 ° C.

    Other drugs

    Disclaimer

    Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.

    The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.

    count views

    Popular Keywords